Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI response includes several polysorbate 80–related claims not supported by the SOOLANTRA label excerpt. Only two statements (ivermectin as active ingredient; polysorbate 80 labeling under inactive ingredients) are supported by the label. The rest are absent or not supported.
Category Scores
Accurate Statements
Ivermectin is the active ingredient.
supported
Polysorbate 80 is typically named on the label under 'Inactive ingredients' or 'Excipients'.
supported
Unsupported Statements
Polysorbate 80 is an excipient that appears in some ivermectin formulations, depending on the specific product and manufacturer.
Not supported by label; polysorbate 80 is not mentioned in the SOOLANTRA description.
Polysorbate 80 is not ivermectin; it is an inactive ingredient.
Not supported by label; polysorbate 80 is not named in the inactive ingredients for this product.
Polysorbate 80 helps with stability and delivery in certain dosage forms.
Not supported by label; no stability/delivery information about polysorbate 80 is provided.
Different ivermectin formulations use different solvents and stabilizers to keep the active drug usable and consistent.
Not supported by label; only this product's ingredients are listed.
If a product is a liquid, it is more likely to include emulsifiers/surfactants such as polysorbate 80.
Not supported by label; no formulation guidance for liquids is provided.
Some solid ivermectin formulations may not include polysorbate 80.
Not supported by label; label details pertain only to this topical cream.
Polysorbate 80 is also listed as Tween 80.
Not supported by label; Tween 80 is not mentioned in the inactive ingredients.
Contradictions
Important Omissions
Approved indication(s) for SOOLANTRA cream are not provided in the excerpt.
Importance:
High
Detailed dosing/administration directions and storage conditions are not provided in the excerpt.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Evaluation is limited to claims about polysorbate 80; no direct safety warnings or contraindications are present in the provided excerpt. Misleading claims about excipients could lead to misinterpretation but do not indicate immediate patient risk from the label alone.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Multiple polysorbate 80–related claims are not supported by the label; missing core label content (indication, dosing, safety) reduces accuracy.
Suggested Improvement
Restrict claims to label-supported content; avoid extrapolating about excipients across formulations; explicitly confirm presence/absence of polysorbate 80 from the product label; include product-specific inactive ingredients if relevant.